Paul Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Paul Chang has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
Theodore Karrison
10 shared publicationsBryan F. Peterson
8 shared publications- Douglas Kyle Hogarth
Department of Medicine, Section of Pulmonary & Critical Care, University of Chicago, Chicago, IL 60637, USA
8 shared publications - Oliver S. Eng
Department of Surgery, University of California Irvine, Orange, USA
8 shared publications Samantha Lomnicki
8 shared publicationsShu-Yuan Xiao
8 shared publications
Latest Publications
- 5 August 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (11) , 1417-1422
Artificial Intelligence and Its Impact on Radiology: Summary of the 2024 Intersociety Summer Conference
- 5 August 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (11) , 1417-1422
Artificial Intelligence and Its Impact on Radiology: Summary of the 2024 Intersociety Summer Conference
- Open Access
- 29 October 2024
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 49, 100879
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma
- 29 October 2024
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 49, 100879
Open AccessPrimary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma
- 1 October 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 313 (1) , e242813
It Might Be Time to Get Serious about Generative AI in Radiology
- 1 October 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 313 (1) , e242813
It Might Be Time to Get Serious about Generative AI in Radiology
- 1 June 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 311 (3) , e241254
One Size Does Not Fit All: AI-assisted Reports Tailored to Provider Needs
- 1 June 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 311 (3) , e241254
One Size Does Not Fit All: AI-assisted Reports Tailored to Provider Needs
- 1 October 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 309 (1) , e230936
Imaging Informatics: Maturing Beyond Adolescence to Enable the Return of the Doctor’s Doctor
- 1 October 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 309 (1) , e230936
Imaging Informatics: Maturing Beyond Adolescence to Enable the Return of the Doctor’s Doctor
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
The one-year and median overall survival (mOS) rates of advanced gastroesophageal adenocarcinomas (GEA) are ∼50% and <12 months, respectively. Baseline spatial and temporal molecular heterogeneity of targetable alterations may be a cause of failure of targeted/immunooncologic therapies. This heterogeneity, coupled with infrequent incidence of some biomarkers, has resulted in stalled therapeutic progress. We hypothesized that a personalized treatment strategy, applied at first diagnosis then serially over up to three treatment lines using monoclonal antibodies combined with optimally sequenced chemotherapy, could contend with these hurdles. This was tested using a novel clinical expansion-platform type II design with a survival primary endpoint. Of 68 patients by intention-to-treat, the one-year survival rate was 66% and mOS was 15.7 months, meeting the primary efficacy endpoint (one-sided P = 0.0024). First-line response rate (74%), disease control rate (99%), and median progression-free survival (8.2 months) were superior to historical controls. The PANGEA strategy led to improved outcomes warranting a larger randomized study.Significance:This study highlights excellent outcomes achieved by individually optimizing chemotherapy, biomarker profiling, and matching of targeted therapies at baseline and over time for GEA. Testing a predefined treatment strategy resulted in improved outcomes versus historical controls. Therapeutic resistance observed in correlative analyses suggests that dual targeted inhibition may be beneficial.This article is highlighted in the In This Issue feature, p. 211
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
The one-year and median overall survival (mOS) rates of advanced gastroesophageal adenocarcinomas (GEA) are ∼50% and <12 months, respectively. Baseline spatial and temporal molecular heterogeneity of targetable alterations may be a cause of failure of targeted/immunooncologic therapies. This heterogeneity, coupled with infrequent incidence of some biomarkers, has resulted in stalled therapeutic progress. We hypothesized that a personalized treatment strategy, applied at first diagnosis then serially over up to three treatment lines using monoclonal antibodies combined with optimally sequenced chemotherapy, could contend with these hurdles. This was tested using a novel clinical expansion-platform type II design with a survival primary endpoint. Of 68 patients by intention-to-treat, the one-year survival rate was 66% and mOS was 15.7 months, meeting the primary efficacy endpoint (one-sided P = 0.0024). First-line response rate (74%), disease control rate (99%), and median progression-free survival (8.2 months) were superior to historical controls. The PANGEA strategy led to improved outcomes warranting a larger randomized study.Significance:This study highlights excellent outcomes achieved by individually optimizing chemotherapy, biomarker profiling, and matching of targeted therapies at baseline and over time for GEA. Testing a predefined treatment strategy resulted in improved outcomes versus historical controls. Therapeutic resistance observed in correlative analyses suggests that dual targeted inhibition may be beneficial.This article is highlighted in the In This Issue feature, p. 211